Helix BioPharma Corp. (HBP.TO, HBP, HBP.F), said Monday that its Board of Directors approved the selection of Robert Verhagen as chief executive officer.
Verhagen is currently a Director for Helix.
William White, chairman and interim CEO of Helix, said, "I am pleased with the selection of Rob from our CEO search. Rob has already contributed significantly to Helix as a Director. I look forward to his leadership of the company taking us forward."
Helix also announced that the Board of Directors approved the voluntarily delisting of its common shares from the NYSE MKT. The company's common shares, however, will continue to trade on the Toronto Stock Exchange.
The company provided written notice to NYSE MKT today of its intent to delist and plans to file a Form 25 with the SEC on or about July 9 to initiate the voluntary delisting. It expects that the delisting will be effective on or about July 19.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.